Grifols, S.A. (GRFS) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↓
8.21
↓-35% vs avg
5yr avg: 12.59
30Y Low8.7·High18.0
P/FCF
↓
7.16
↓-46% vs avg
5yr avg: 13.30
30Y Low8.5·High98.7
P/B Ratio
↓
0.57
↓-33% vs avg
5yr avg: 0.85
30Y Low0.6·High5.8
ROE
↑
4.8%
↓+93% vs avg
5yr avg: 2.5%
30Y Low1%·High46%
Debt/EBITDA
↓
5.40
↓-31% vs avg
5yr avg: 7.87
30Y Low2.0·High10.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GRFS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Grifols, S.A. trades at 11.2x earnings, 77% below its 5-year average of 49.2x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 50%. On a free-cash-flow basis, the stock trades at 7.2x P/FCF, 46% below the 5-year average of 13.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.2B | $6.4B | $5.1B | $7.9B | $5.8B | $7.7B | $12.6B | $15.5B | $12.6B | $15.7B | $11.0B |
| Enterprise Value | $15.2B | $14.3B | $14.2B | $18.3B | $15.0B | $17.2B | $19.0B | $22.6B | $17.6B | $20.8B | $15.0B |
| P/E Ratio → | 11.16 | 16.40 | 32.35 | 128.44 | 27.42 | 41.59 | 25.26 | 24.78 | 21.10 | 23.63 | 20.09 |
| P/S Ratio | 0.74 | 0.88 | 0.70 | 1.19 | 0.95 | 1.55 | 2.37 | 3.03 | 2.80 | 3.63 | 2.71 |
| P/B Ratio | 0.57 | 0.84 | 0.59 | 1.05 | 0.72 | 1.05 | 1.88 | 2.01 | 2.68 | 4.32 | 2.95 |
| P/FCF | 7.16 | 8.47 | 9.53 | — | — | 21.89 | 15.23 | 98.69 | 29.26 | 30.23 | 42.19 |
| P/OCF | 5.35 | 6.33 | 5.61 | 35.93 | — | 12.82 | 11.38 | 27.17 | 17.05 | 18.63 | 19.87 |
P/E links to full P/E history page with 30-year chart
GRFS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Grifols, S.A.'s enterprise value stands at 8.2x EBITDA, 35% below its 5-year average of 12.6x. The Healthcare sector median is 14.2x, placing the stock at a 42% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.98 | 1.96 | 2.78 | 2.47 | 3.48 | 3.55 | 4.43 | 3.92 | 4.82 | 3.70 |
| EV / EBITDA | 8.21 | 8.82 | 8.69 | 14.93 | 12.55 | 17.98 | 14.40 | 15.76 | 14.37 | 17.07 | 13.13 |
| EV / EBIT | 11.20 | 12.03 | 13.53 | 25.37 | 19.14 | 29.38 | 17.22 | 19.80 | 17.57 | 22.01 | 15.91 |
| EV / FCF | — | 19.01 | 26.69 | — | — | 49.10 | 22.85 | 144.29 | 40.88 | 40.11 | 57.50 |
GRFS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Grifols, S.A. earns an operating margin of 16.4%. Operating margins have expanded from 11.9% to 16.4% over the past 3 years, signaling improving operational efficiency. ROE of 4.8% is modest. ROIC of 5.4% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.7% | 35.7% | 38.7% | 37.7% | 36.5% | 39.8% | 42.2% | 45.9% | 45.7% | 49.8% | 47.2% |
| Operating Margin | 16.4% | 16.4% | 16.5% | 11.9% | 12.9% | 12.1% | 18.7% | 22.2% | 22.2% | 23.2% | 23.2% |
| Net Profit Margin | 5.3% | 5.3% | 2.2% | 0.6% | 3.1% | 3.8% | 11.6% | 12.3% | 13.3% | 15.3% | 13.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.8% | 4.8% | 1.9% | 0.5% | 2.4% | 2.7% | 8.6% | 10.1% | 14.3% | 18.0% | 15.5% |
| ROA | 1.9% | 1.9% | 0.7% | 0.2% | 0.9% | 1.1% | 3.8% | 4.2% | 5.1% | 6.3% | 5.5% |
| ROIC | 5.4% | 5.4% | 5.0% | 3.3% | 3.5% | 3.0% | 5.4% | 6.9% | 8.1% | 9.1% | 9.6% |
| ROCE | 6.4% | 6.4% | 6.3% | 4.1% | 4.5% | 4.0% | 6.7% | 8.3% | 9.4% | 10.6% | 10.7% |
GRFS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Grifols, S.A. carries a Debt/EBITDA ratio of 5.4x, which is highly leveraged (68% above the sector average of 3.2x). Net debt stands at $7.9B ($8.7B total debt minus $825M cash). Interest coverage of just 2.0x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.15 | 1.15 | 1.17 | 1.47 | 1.22 | 1.39 | 1.03 | 1.04 | 1.28 | 1.65 | 1.31 |
| Debt / EBITDA | 5.40 | 5.40 | 6.19 | 8.97 | 8.17 | 10.65 | 5.25 | 5.56 | 4.93 | 4.93 | 4.28 |
| Net Debt / Equity | — | 1.04 | 1.06 | 1.40 | 1.15 | 1.30 | 0.94 | 0.93 | 1.06 | 1.41 | 1.07 |
| Net Debt / EBITDA | 4.89 | 4.89 | 5.59 | 8.53 | 7.71 | 9.96 | 4.81 | 4.98 | 4.09 | 4.20 | 3.50 |
| Debt / FCF | — | 10.54 | 17.15 | — | — | 27.20 | 7.63 | 45.61 | 11.63 | 9.88 | 15.31 |
| Interest Coverage | 1.98 | 1.98 | 1.35 | 1.40 | 1.76 | 2.50 | 3.87 | 3.52 | 3.65 | 3.79 | 4.12 |
GRFS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Grifols, S.A.'s current ratio of 2.51x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 0.88x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.64x to 2.51x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.51 | 2.51 | 2.66 | 2.64 | 2.32 | 1.59 | 2.37 | 3.92 | 2.77 | 3.01 | 2.91 |
| Quick Ratio | 0.88 | 0.88 | 1.01 | 1.14 | 0.72 | 0.94 | 0.87 | 2.21 | 1.22 | 1.35 | 1.38 |
| Cash Ratio | 0.41 | 0.41 | 0.46 | 0.28 | 0.29 | 0.77 | 0.44 | 1.80 | 0.82 | 0.91 | 0.84 |
| Asset Turnover | — | 0.37 | 0.34 | 0.31 | 0.29 | 0.26 | 0.35 | 0.29 | 0.36 | 0.40 | 0.40 |
| Inventory Turnover | 1.41 | 1.41 | 1.24 | 1.18 | 1.19 | 1.31 | 1.54 | 1.05 | 1.25 | 1.33 | 1.30 |
| Days Sales Outstanding | — | 42.66 | 54.62 | 38.36 | 46.60 | 32.12 | 26.19 | 37.81 | 32.67 | 32.57 | 47.63 |
GRFS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Grifols, S.A. returns 5.1% to shareholders annually — split between a 2.8% dividend yield and 2.3% buyback yield. The payout ratio of 31.8% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 9.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.8% | 1.9% | 0.0% | — | 0.0% | 3.3% | 0.9% | 1.5% | 2.2% | 1.4% | 2.0% |
| Payout Ratio | 31.8% | 31.8% | 0.6% | — | 0.3% | 133.8% | 18.3% | 38.2% | 46.7% | 32.9% | 39.6% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.0% | 6.1% | 3.1% | 0.8% | 3.6% | 2.4% | 4.0% | 4.0% | 4.7% | 4.2% | 5.0% |
| FCF Yield | 14.0% | 11.8% | 10.5% | — | — | 4.6% | 6.6% | 1.0% | 3.4% | 3.3% | 2.4% |
| Buyback Yield | 2.3% | 1.9% | 0.0% | 0.0% | 0.1% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 5.1% | 3.9% | 0.0% | 0.0% | 0.1% | 4.9% | 0.9% | 1.5% | 2.2% | 1.4% | 2.1% |
| Shares Outstanding | — | $681M | $680M | $680M | $680M | $682M | $686M | $664M | $685M | $684M | $684M |
Peer Comparison
Compare GRFS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GRFSYou | $6B | 11.2 | 8.2 | 7.2 | 35.7% | 16.4% | 4.8% | 5.4% | 5.4 |
 TAK | $48B | 39.2 | 9.1 | 9.7 | 51.1% | 12.0% | 2.8% | 3.7% | 3.7 |
 CSL | $15B | 21.1 | 13.8 | 15.2 | 35.7% | 19.9% | 34.8% | 20.6% | 2.4 |
 BHVN | $2B | -2.3 | — | — | — | — | -310.8% | -242.1% | — |
 OCSL | $1B | 29.3 | 16.0 | 7.1 | 87.2% | 50.4% | 2.3% | 3.7% | 9.8 |
 BCRX | $2B | 7.6 | 6.7 | 5.9 | 97.8% | 39.0% | — | 96.7% | 1.4 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 ALNY | $38B | 122.9 | 67.9 | 82.1 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ARCT | $205M | -3.0 | — | — | 95.5% | -111.5% | -28.9% | -277.1% | — |
 BIO | $8B | 10.1 | 18.0 | 20.3 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GRFS — Frequently Asked Questions
Quick answers to the most common questions about buying GRFS stock.
What is Grifols, S.A.'s P/E ratio?
Grifols, S.A.'s current P/E ratio is 11.2x. The historical average is 36.3x.
What is Grifols, S.A.'s EV/EBITDA?
Grifols, S.A.'s current EV/EBITDA is 8.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.1x.
What is Grifols, S.A.'s ROE?
Grifols, S.A.'s return on equity (ROE) is 4.8%. The historical average is 15.1%.
Is GRFS stock overvalued?
Based on historical data, Grifols, S.A. is trading at a P/E of 11.2x. Compare with industry peers and growth rates for a complete picture.
What is Grifols, S.A.'s dividend yield?
Grifols, S.A.'s current dividend yield is 2.84% with a payout ratio of 31.8%.
What are Grifols, S.A.'s profit margins?
Grifols, S.A. has 35.7% gross margin and 16.4% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Grifols, S.A. have?
Grifols, S.A.'s Debt/EBITDA ratio is 5.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.